Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash

Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutive capital received, under certain circumstances

Read more at globenewswire.com